gainbot
BriefMoversScreensSectorsEarningsIPOsNewsDividends & splitsScreenerWatchlistLearn
NASDAQ · VTGNHealthcarePharmaceuticals

Vistagen Therapeutics, Inc. Common Stock (VTGN)

$0.1784+6.22%
Close Nov 4, 2026 · split-adjusted
Nov 2, 2026$0.17▼ 96.05% in range
Nov 3, 2025Low $0.17 · High $4.90Nov 2, 2026
What changed · written from our data
As of Nov 4, 2026

Vistagen Therapeutics closed at $0.18 on Nov 4, up 6.22%, 96.4% below its 52-week closing high. Volume of 547.1K shares was 0.70× its 20-day average (below normal).

Split-adjusted performance: -28.8% over one month, -70.8% over six months, -95.8% over one year.

In the quarter ended Jun 30, 2026, revenue was $1.48M, up 504.9% from a year earlier, with a net margin of -882.8%.

Short interest was 2.5M shares at the Oct 15 settlement, down 34.1% from the prior report (5.7% of float, 2.2 days to cover).

Market cap$7.9M44.4M shares
Revenue · quarter$1.5M+504.9% YoY
Diluted EPS$-0.30—
P/E · TTM—P/S 3.2×
Net margin-882.8%Gross 100.0%
Dividend yieldNone
52-week range0.17 – 4.90−96.4% from high
Volume547.1K0.70× 20-day avg
Volatility · 60d106.0%Annualised
Short % of float5.7%2.2 days to cover
Net cash$31.7MCash $31.7M
Next earnings—Not scheduled
Split-adjusted performance
1W +5.0%1M −28.8%3M −37.1%6M −70.8%YTD −73.0%1Y −95.8%3Y −94.2%5Y −99.7%

Earnings reactions

History →

No reported quarters with price history yet.

Rank within Pharmaceuticals

Percentile among 420 companies (100 = best)

6-month momentum12
Revenue growth93
Net margin23
Value (low P/E)—
Size12

Industry medians: 6-month return −25.3%, revenue growth +6.2%, net margin −33.8%, P/E 16.1×.

Short interest

Details →
Shares short2.5M−34.1% vs prior
Days to cover2.2Settled Oct 15
% of float5.7%
Short vol. 10d54.3%of daily volume

Closest peers by size in Pharmaceuticals

CompanyPriceToday6MRev. growthNet marginP/EMkt cap
VTGNVistagen Therapeutics$0.1784+6.22%−70.8%+504.9%−882.8%—$7.9M
SNGXSoligenix$0.3570+0.25%+7.9%———$7.8MCompare
ALZNAlzamend Neuro$1.57+7.19%+42.3%———$7.6MCompare
LTRNLantern Pharma$0.5651−6.18%−73.6%———$8.4MCompare
ENSCEnsysce Biosciences$0.3730−1.24%−4.4%−15.1%−220.8%—$7.3MCompare
KPRXKiora Pharmaceuticals$1.64−5.20%−34.7%———$7.3MCompare
ACTUActuate Therapeutics$0.3604+2.97%−87.9%———$8.7MCompare
LEXXLexaria Bioscience$4.12+2.23%−59.3%−100.0%——$8.7MCompare
MBRXMoleculin Biotech$8.56+3.11%−82.7%———$8.7MCompare

News about Vistagen Therapeutics

All news →
Kuehn Law Encourages Investors of Vistagen Therapeutics, Inc. to Contact Law FirmBenzinga · Jun 1, 2026▼ NegativeVTGN DEADLINE: ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Vistagen Therapeutics, Inc. Investors to Secure Counsel Before Important March 16 Deadline in Securities Class Action - VTGNGlobeNewswire Inc. · Mar 14, 2026▼ NegativeBronstein, Gewirtz & Grossman LLC Urges Vistagen Therapeutics, Inc. Investors to Act: Class Action Filed Alleging Investor HarmGlobeNewswire Inc. · Mar 12, 2026▼ NegativeVTGN Investors Have Opportunity to Lead Vistagen Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law FirmGlobeNewswire Inc. · Mar 9, 2026▼ NegativeVTGN DEADLINE NOTICE: ROSEN, A TOP RANKED LAW FIRM, Encourages Vistagen Therapeutics, Inc. Investors to Secure Counsel Before Important March 16 Deadline in Securities Class Action - VTGNGlobeNewswire Inc. · Mar 7, 2026▼ Negative

Quick answers

What does Vistagen Therapeutics do?
Vistagen Therapeutics Inc is a late clinical-stage therapeutics company focused on developing and commercializing medicines for patients with social anxiety disorder, depression, menopausal hot flashes, psychomotor impairment due to mental fatigue, and cancer cachexia. The company is engaged in developing intranasal product candidates called pherines, which leverage the understanding of nose-to-brain neurocircuitry.
What is VTGN's market cap?
$7.92M, based on the Nov 4 close of $0.18.
Does Vistagen Therapeutics pay a dividend?
No regular cash dividend has been paid in the last year.
How much of VTGN is sold short?
2.5M shares, 5.7% of float, as of Oct 15, 2026.
What sector is VTGN in?
Healthcare, in the Pharmaceuticals industry.

About Vistagen Therapeutics

Vistagen Therapeutics Inc is a late clinical-stage therapeutics company focused on developing and commercializing medicines for patients with social anxiety disorder, depression, menopausal hot flashes, psychomotor impairment due to mental fatigue, and cancer cachexia. The company is engaged in developing intranasal product candidates called pherines, which leverage the understanding of nose-to-brain neurocircuitry. Vistagen's pherine pipeline consists of various product candidates like: Fasedienol, Itruvone, PH15, Refisolone, and PH284, which are being developed to provide treatment for a variety of disorders. Additionally, it is seeking potential partners for the further clinical development and commercialization of an oral drug candidate, AV-101, to treat certain neurological disorders.

HQ: South San Francisco, CA41 employeesListed Jul 1, 2009vistagen.com

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology